Streetbeat News

Products Services

INVZ

Innoviz Technologies Ltd. (INVZ) will participate in CES 2024, showcasing the BMW i7 and Volkswagen ID. Buzz, both integrated with Innoviz's LiDAR technology. The BMW i7, featuring InnovizOne LiDAR, is available for order in Germany, with deliveries starting March 2024. The VW ID. Buzz, equipped with InnovizTwo LiDAR, highlights level 4 autonomous capabilities. Innoviz will also demonstrate Innoviz360 and has been named a CES 2024 Innovation Awards Honoree for its InnovizCore Compute Module.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:37 pm

SYRS

Syros Pharmaceuticals has announced its anticipated milestones for 2024 regarding Tamibarotene. The company expects to complete enrollment of 190 patients for the primary analysis in the SELECT-MDS-1 Phase 3 trial in the first quarter of 2024, with pivotal CR data anticipated by mid-fourth quarter of 2024. Additional data from the SELECT-AML-1 Phase 2 trial is also expected in 2024, following initial data showing a 100% CR/CRi rate and a favorable tolerability profile. Syros has also strengthened its balance sheet with approximately $45.0 million in gross proceeds from recent equity financing, extending its cash runway into the second quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:37 pm

STXS

Stereotaxis, Inc. has announced that the first patients have been treated using its MAGiC Ablation Catheter. This marks a significant milestone for the company as it showcases the application of its technology in patient care. The MAGiC Ablation Catheter is a part of Stereotaxis' innovative technology offerings in the field of robotic cardiology, which aims to improve patient outcomes and procedural efficiency.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:37 pm

TMCI

Treace Medical Concepts, Inc. (TMCI) reported preliminary Q4 FY23 revenue between $61.8M-$62.2M, surpassing the consensus estimate of $58.89M. The company also projected FY23 revenues to be between $186.7M-$187.1M, which is higher than the consensus of $183.86M. TMCI saw a record high average revenue per Lapiplasty procedure kit sold at approximately $6,437, marking a 9% increase from the previous year. The company also reported a significant growth in active surgeons using their products, with about 164 new additions in Q4 and 468 for the full year, ending with approximately 2,855 active surgeons, a 20% increase from the previous year. Additionally, TMCI ended Q4 with 227 direct quota carrying sales representatives, a 35% increase from the end of 2022, contributing to 82% of the revenue in Q4.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:36 pm

CDIO

Cardio Diagnostics Holdings has been granted a patent in India, numbered 484488, for a kit that determines the methylation status of a CpG dinucleotide and a genotype of a single nucleotide polymorphism. The company now holds patents in multiple regions globally, including the United States, Europe, Australia, China, and Hong Kong, with additional patents pending worldwide.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:36 pm

EDIT

Editas Medicine, Inc. (NASDAQ: EDIT) announced its 2024 strategic priorities and anticipated milestones at the J.P. Morgan Healthcare Conference. The company plans to present reni-cel clinical data updates, initiate the RUBY trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue sublicensing its foundational IP. Editas has a strong financial position with a runway into 2026. The company's focus remains on developing reni-cel towards BLA and commercialization, building an in vivo pipeline, and increasing business development activities. Revenue is expected from licensing agreements with Vertex Pharmaceuticals and Vor Bio.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:35 pm

HRMY

Harmony Biosciences projects 2024 net product revenue between $700M-$720M and has repurchased $50M in common stock in Q4 2023, totaling $100M for the year. The company plans to continue share repurchases in 2024. Key priorities include growing WAKIX for narcolepsy, advancing the pipeline with several trials, and disciplined capital allocation to maximize shareholder value. The financial data is preliminary and unaudited.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:34 pm

YTEN

Yield10 Bioscience has submitted a request to the USDA-APHIS for a regulatory status review of its genetically designed Camelina plants, which are engineered to produce EPA and DHA, key components of Omega-3 oil. The review is a step towards commercializing the product, which could have implications for the agriculture and health industries.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:32 pm

EDAP

EDAP TMS SA (NASDAQ:EDAP) announced preliminary results for Q4 2023, reporting a record number of twelve Focal One Systems placements, including ten capital sales. The company also saw a record quarter for sales of ExactVu Micro-Ultrasound systems. The demand came from both academic medical centers and community hospitals. CEO Ryan Rhodes highlighted the momentum of the commercial team and the growing adoption of Focal One in prostate cancer management. Final Q4 financial results are expected in March.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:32 pm

AFMD

Affimed N.V. has reaffirmed its guidance for the release of data readouts for two of its clinical trials, AFM24-102 and LuminICE-203, which are expected in the first half of 2024. This confirmation may indicate progress in the company's clinical programs and could be a positive signal to investors looking forward to these milestones.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:29 pm